JP2011528654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528654A5
JP2011528654A5 JP2011516733A JP2011516733A JP2011528654A5 JP 2011528654 A5 JP2011528654 A5 JP 2011528654A5 JP 2011516733 A JP2011516733 A JP 2011516733A JP 2011516733 A JP2011516733 A JP 2011516733A JP 2011528654 A5 JP2011528654 A5 JP 2011528654A5
Authority
JP
Japan
Prior art keywords
formula
compound
optionally substituted
compound according
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516733A
Other languages
English (en)
Japanese (ja)
Other versions
JP6084770B2 (ja
JP2011528654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048943 external-priority patent/WO2009158668A1/en
Publication of JP2011528654A publication Critical patent/JP2011528654A/ja
Publication of JP2011528654A5 publication Critical patent/JP2011528654A5/ja
Application granted granted Critical
Publication of JP6084770B2 publication Critical patent/JP6084770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516733A 2008-06-26 2009-06-26 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート Active JP6084770B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13314808P 2008-06-26 2008-06-26
US61/133,148 2008-06-26
US19205008P 2008-09-15 2008-09-15
US61/192,050 2008-09-15
PCT/US2009/048943 WO2009158668A1 (en) 2008-06-26 2009-06-26 Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015126754A Division JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Publications (3)

Publication Number Publication Date
JP2011528654A JP2011528654A (ja) 2011-11-24
JP2011528654A5 true JP2011528654A5 (enExample) 2012-08-16
JP6084770B2 JP6084770B2 (ja) 2017-02-22

Family

ID=41444985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011516733A Active JP6084770B2 (ja) 2008-06-26 2009-06-26 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート
JP2015126754A Pending JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015126754A Pending JP2015172078A (ja) 2008-06-26 2015-06-24 制御された薬剤放出速度を有するプロドラッグ及び薬剤−高分子のコンジュゲート

Country Status (7)

Country Link
US (2) US8680315B2 (enExample)
EP (1) EP2306986B1 (enExample)
JP (2) JP6084770B2 (enExample)
CN (1) CN102076331B (enExample)
DK (1) DK2306986T3 (enExample)
ES (1) ES2672526T3 (enExample)
WO (1) WO2009158668A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5964815B2 (ja) * 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2571496A4 (en) * 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
EP2729179B1 (en) 2011-06-06 2020-09-23 Starpharma Pty Ltd Macromolecules
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
AU2012304337B2 (en) 2011-09-07 2015-05-07 Prolynx Llc Hydrogels with biodegradable crosslinking
WO2013059323A1 (en) * 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
EP2850201A4 (en) * 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted administration of proteins for the treatment of cancer
CN106232131A (zh) * 2013-10-22 2016-12-14 普洛林克斯有限责任公司 生长抑素和其类似物的结合物
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
MA40524A (fr) 2014-09-26 2021-03-17 Bayer Pharma AG Dérivés d'adrénomédulline stabilisés et leur utilisation
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
CN109414469A (zh) * 2016-03-16 2019-03-01 普罗林科斯有限责任公司 艾塞那肽类似物的缓释偶联物
CN106177977B (zh) * 2016-07-11 2020-09-04 天津科技大学 一种抗肿瘤药物三元偶联物及合成和应用
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2019140266A1 (en) 2018-01-12 2019-07-18 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
BR112021000658A2 (pt) 2018-07-19 2021-04-13 Starpharma Pty Ltd Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
JPWO2020050378A1 (ja) * 2018-09-06 2021-08-30 生化学工業株式会社 第3級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
WO2020067507A1 (ja) * 2018-09-28 2020-04-02 生化学工業株式会社 第1級アミン化合物又は第2級アミン化合物-酸性多糖コンジュゲートとその製造方法
CN114286693A (zh) 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
BR112022002308A2 (pt) 2019-08-07 2022-04-26 Prolynx Llc Esterilização a vapor de hidrogéis reticulados por ligantes beta-eliminativos
CN110423355B (zh) * 2019-08-29 2021-09-14 武汉轻工大学 羧甲基化莲藕多糖-曲古霉素a轭合物的制备方法
EP4139340A1 (en) 2020-04-22 2023-03-01 Merck Sharp & Dohme LLC Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
US20240261425A1 (en) * 2021-04-09 2024-08-08 Nanjing University Conjugate and the preparing method and use thereof
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE55594T1 (de) * 1986-05-16 1990-09-15 Eka Nobel Ab Optisch aktives reagens und verfahren zur determinierung von enantiomeren aminverbindungen.
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6251897B1 (en) * 1996-07-31 2001-06-26 Nikken Chemicals Co., Ltd 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
JPH11130711A (ja) * 1997-10-24 1999-05-18 Teijin Ltd 1α,24,25−トリヒドロキシビタミンD3類の合成中間体およびその製造法
WO2000029386A1 (en) * 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6114566A (en) * 1999-05-24 2000-09-05 Board Of Trustees Operating Michigan State University 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof
WO2001017515A1 (en) * 1999-09-03 2001-03-15 School Of Pharmacy, University Of London Degradable polymers
US6861162B2 (en) 2002-08-28 2005-03-01 Cityu Research Ltd. Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
EP1620118B1 (en) * 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
WO2004089279A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
ES2741524T3 (es) * 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
JP2006067889A (ja) 2004-09-01 2006-03-16 Japan Science & Technology Agency Peoと二本鎖核酸のコンジュゲート
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
AU2006280600B2 (en) 2005-08-17 2012-01-19 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
JP5224016B2 (ja) * 2006-03-10 2013-07-03 晃二 有光 感活性エネルギー線塩基発生剤、感活性エネルギー線塩基発生剤組成物、塩基反応性組成物及びパターン形成方法
WO2008058016A2 (en) 2006-11-02 2008-05-15 University Of Virginia Patent Foundation Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
HUE029926T2 (en) * 2008-04-29 2017-04-28 Ascendis Pharma Growth Disorders Div As Pegylated recombinant human growth hormone compounds

Similar Documents

Publication Publication Date Title
JP2011528654A5 (enExample)
JP5249016B2 (ja) タキサン類の高分子結合体
CN102985462B (zh) 支链异聚乙二醇和中间体
JP2013525080A5 (enExample)
JP2016528174A5 (enExample)
JP2008524338A5 (enExample)
CN102050953B (zh) 一种可还原降解超分子水凝胶的制备方法
JP2013500256A5 (enExample)
JP2012526548A5 (enExample)
JP2015528002A5 (enExample)
JP6159973B2 (ja) ポリオキサゾリンポリマー及びそれらの製造方法、これらのポリマーのコンジュゲート並びにそれらの医学的使用
JP2014528466A5 (enExample)
JP2010521485A5 (enExample)
JP2011080089A5 (enExample)
JP2013523896A5 (enExample)
JP2016153410A5 (enExample)
JP2012504608A5 (enExample)
JP2014521661A5 (enExample)
WO2008041610A1 (fr) Mélange d'un dérivé de résorcinol avec un polymère
JP2012502990A5 (enExample)
JP2005504006A5 (enExample)
JP2009521545A5 (enExample)
JP2009535358A5 (enExample)
JP2009504783A5 (enExample)
JP2009502743A5 (enExample)